Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
January 09 2023 - 08:05AM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to develop and launch the first FDA-approved
ophthalmic formulation of bevacizumab for use in
retinal indications, today announced that Russ Trenary,
President and Chief Executive Officer of Outlook Therapeutics will
present at the Virtual Investor 2023 Companies to Watch
Event on Tuesday, January 17, 2023 at 11:00 AM ET.
A live video webcast of the presentation will be
available on the Events page of the Investors section of Outlook
Therapeutics’ website (outlooktherapeutics.com). A webcast replay
will be available two hours following the live presentation and
will be accessible for 90 days.About Outlook Therapeutics,
Inc.Outlook Therapeutics is a biopharmaceutical company
working to develop and launch ONS-5010/ LYTENAVA™
(bevacizumab-vikg) as the first FDA-approved ophthalmic formulation
of bevacizumab for use in retinal indications, including wet AMD,
DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission
for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29,
2023. The submission is supported by Outlook Therapeutics’ wet AMD
clinical program, which consists of three clinical trials: NORSE
ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab
is approved, Outlook Therapeutics expects to commercialize it as
the first and only FDA-approved ophthalmic formulation of
bevacizumab for use in treating retinal diseases in the United
States, United Kingdom, Europe, Japan, and other markets. As part
of the Company’s multi-year commercial planning process, and in
anticipation of potential FDA approval in August 2023, Outlook
Therapeutics and AmerisourceBergen have entered into a strategic
commercialization agreement to expand the Company’s reach for
connecting to retina specialists and their patients.
AmerisourceBergen will provide third-party logistics (3PL) services
and distribution, as well as pharmacovigilance services in the
United States. For more information, please visit
www.outlooktherapeutics.com.
CONTACTS:Media Inquiries:Anna
ArmyAccount SupervisorLaVoie Health ScienceT:
617-351-0246aarmy@lavoiehealthscience.com
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Nov 2023 to Dec 2023
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Dec 2022 to Dec 2023